A new drug for hair loss-Tofacitinib
Not Applicable
Not yet recruiting
- Conditions
- Health Condition 1: L639- Alopecia areata, unspecified
- Registration Number
- CTRI/2022/09/045386
- Lead Sponsor
- Department of Dermatology venereology and leprosy Burdwan medical college and hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Alopecia areata involving more than 50% of scalp surface area.
Age- 15-60 years
Exclusion Criteria
Immunosupressed patients like HIV,TB, Hepatitis
Patients on chemotherapy.
Pregnancy and lactation
Patients with psoriasis or seborrhoeic dermatitis.
Patients treated with any topical or systemic therapy within 3 month of 1st visit
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary- to compare the response of treatment in 2 group alloted. <br/ ><br>secondary- to evaluate safety of drugTimepoint: <br/ ><br>Treatment to be given for 16 weeks and follow up 12 weeks
- Secondary Outcome Measures
Name Time Method Comparing maintenance of response post treatment along with assessment of side effectsTimepoint: After every month during treatment and follow up period